Facebook Instagram X-twitter Linkedin Youtube Spotify

Duchenne News Tags: Catalyst Pharmaceuticals

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Upsher-Smith Wave Life Sciences
March 13, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy

Following the FDA approval on October 26, 2023, AGAMREE is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.
Read More
October 30, 2023

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst shares that the U.S. Food and Drug Administration (FDA) approved a new steroid treatment for Duchenne muscular dystrophy.
Read More
Register Now

Experience the magic this summer!

Apply Today

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Register Today

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Give Today

Accessible Vehicle Fund Applications Open

Apply Today